CliffBio
small molecule

OHTUVAYRE

ENSIFENTRINE

Loss of exclusivityJune 2044latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC

Drug detail

Brand nameOHTUVAYRE
Active ingredientENSIFENTRINE
Strength3MG/2.5ML
Dosage formSUSPENSION
RouteINHALATION
ModalitySmall molecule
FDA approvalJune 2024
Marketing statusRX

Listed patents

PatentExpiresType
12251384June 2044product
12409180February 2043product
9956171September 2035product
10945950September 2035product
9062047August 2031substance

Regulatory exclusivity

CodeExpires
NCEJune 2029

More from MERCK SHARP AND DOHME LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.